Image Place holder

Roohi Ismail-Khan, MD, MSc


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt McKinley Outpatient Center
Overview

Cancer Types Treated: Breast Cancer, Ductal Carcinoma In Situ , Inflammatory Breast Cancer , Invasive Ductal Carcinoma , Triple Negative Breast Cancer

Dr. Roohi Ismail-Khan is a medical oncologist in the Department of Breast Oncology at Moffitt Cancer Center. Dr. Ismail-Khan’s research interests include reducing or eliminating long-term effects of chemotherapy to improve quality of life. She is also focused on triple negative breast cancer; an aggressive disease that may respond well to chemotherapy, but often recurs and spreads. She serves as principal investigator on multiple investigator and pharmaceutical sponsored clinical trials. She is the co-director of the new Cardio-Oncology program working closely with Dr. Fradley, director of the program. Dr. Ismail-Kahn is also an active teacher/mentor for USF medical students, internal medicine USF residents, and medical oncology fellows.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine

Fellowship:

  • University of South Florida, Tampa, FL - Medical Oncology

Residency:

  • University of South Florida, Tampa, FL - Internal Medicine

Medical School:

  • St. George's University of Medicine, Grenada, WI - MD
Participating Trials

CLINICAL TRIAL 18356
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18386
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Condition: Breast
Intervention: Not Applicable
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18862
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); SGN-LIV1A; Trastuzumab; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18621
A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast
Intervention: Adriamycin (doxorubicin); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 19340
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Condition: Breast
Intervention: Herceptin (Trastuzumab); Not Applicable; Placebo; Trastuzumab; Tucatinib; Xeloda (capecitabine); capecitabine; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 16664
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Metastatic and Locally Advanced Breast Cancer
Condition: Breast
Intervention: Adriamycin (doxorubicin); Taxol (paclitaxel); Triciribine (TCN-PM (0002)); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 19393
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage,Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Condition: Breast
Intervention: Abemaciclib; LY2835219 (Abemaciclib)
Open

CLINICAL TRIAL 19394
An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2-Negative, Brca-Mutant Breast Cancer Patients
Condition: Breast
Intervention: Niraparib
Open

CLINICAL TRIAL 19603
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); SGN-LIV1A
Open

CLINICAL TRIAL 19632
A Phase Ib/II, Open-Label, Multicenter,Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab; Cobimetinib; Eribulin Mesylate; Gemzar (gemcitabine); Ipatasertib; Not Applicable; SGN-LIV1A; Xeloda (capecitabine); capecitabine; gemcitabine
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB. Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. J Clin Oncol. 2018 Sep. Pubmedid: 30235087.
  • Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, Antonia S. A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer. Oncotarget. 2018 Feb;9(11):10110-10117. Pubmedid: 29515795. Pmcid: PMC5839376.
  • Park JY, Lengacher CA, Reich RR, Alinat CB, Ramesar S, Le A, Paterson CL, Pleasant ML, Park HY, Kiluk J, Han H, Ismail-Khan R, Kip KE. Translational genomic research: the role of genetic polymorphisms in MBSR program among breast cancer survivors (MBSR[BC]). Transl Behav Med. 2018 Aug. Pubmedid: 30137607.
  • Fradley MG, Brown AC, Shields B, Viganego F, Damrongwatanasuk R, Patel AA, Hartlage G, Roper N, Jaunese J, Roy L, Ismail-Khan R. Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience. Oncol Rev. 2017 Jun;11(2):340. Pubmedid: 28781723. Pmcid: PMC5523022.
  • Reich RR, Lengacher CA, Alinat CB, Kip KE, Paterson C, Ramesar S, Han HS, Ismail-Khan R, Johnson-Mallard V, Moscoso M, Budhrani-Shani P, Shivers S, Cox CE, Goodman M, Park J. Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. J Pain Symptom Manag. 2017 Jan;53(1):85-95. Pubmedid: 27720794.
  • Sajjad M, Fradley M, Sun W, Kim J, Zhao X, Pal T, Ismail-Khan R. An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity. Genes (Basel). 2017 02;8(2). Pubmedid: 28157161. Pmcid: PMC5333048.
  • Fradley MG, Viganego F, Kip K, Martin A, Patel AA, Ismail-Khan R, Chae S, Herweg B, Labovitz A. Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart. 2017;4(2):e000701. Pubmedid: 29344369. Pmcid: PMC5761288.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Rosa M, Han HS, Ismail-Khan R, Allam-Nandyala P, Bui MM. Beta-catenin Expression Patterns in Matched Pre- and Post-Neoadjuvant Chemotherapy-Resistant Breast Cancer. Ann Clin Lab Sci. 2015 Jan;45(1):10-16. Pubmedid: 25696004.
  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557. Pmcid: PMC4226672.
  • Williams M, Eatrides J, Kim J, Talwar H, Esposito N, Szabunio M, Ismail-Khan R, Kiluk J, Lee M, Laronga C, Khakpour N. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy. Am J Surg. 2013 Oct;206(4):567-573. Pubmedid: 23809673.
  • Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata. J Clin Oncol. 2013 Jun;31(17):2128-2135. Pubmedid: 23650416. Pmcid: PMC4881332.
  • Bardhan P, Bui MM, Minton S, Loftus L, Carter WB, Laronga C, Ismail-Khan R. HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature. Ann Clin Lab Sci. 2012 May;42(2):135-139. Pubmedid: 22585608.
  • Donovan KA, Boyington AR, Ismail-Khan R, Wyman JF. Urinary symptoms in breast cancer: a systematic review. Cancer. 2012 Feb;118(3):582-593. Pubmedid: 21751193. Pmcid: PMC3193898.
  • Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb;30(5):533-538. Pubmedid: 22231041. Pmcid: PMC3295555.
  • Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Brit J Cancer. 2011 Jun;104(12):1828-1835. Pubmedid: 21559012. Pmcid: PMC3111195.
  • Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010 Jul;17(3):173-176. Pubmedid: 20664514.
  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.
  • Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell B. 2007 Oct;39(7-8):1318-1328. Pubmedid: 17600754. Pmcid: PMC3167070.
  • Ismail-Khan R, Robinson L, Williams CC J, Garrett C, Bepler G, Simon G. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006 Oct;13(4):255-263. Pubmedid: 17075562.
  • Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul;13(3):211-217. Pubmedid: 16885917.